Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021
February 24 2021 - 7:00AM
Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company
focused on developing transformative therapies for rare, monogenic
central nervous system disorders, today announced that it will host
a conference call and live webcast at 8:30 a.m. ET on Wednesday,
March 3, 2021 to report its fourth quarter and full-year 2020
financial results and discuss recent business highlights.
To access the live conference call, please
dial 833-528-0605 (domestic) or 830-221-9711
(international) and refer to conference ID 6758094. A live audio
webcast of the event will be available on the Investors & Media
section of Passage Bio’s website at investors.passagebio.com. The
archived webcast will be available on Passage Bio's website
approximately two hours after the completion of the event and for
30 days following the call.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide
life-transforming gene therapies for patients with rare, monogenic
CNS diseases that replace their suffering with boundless
possibility, all while building lasting relationships with the
communities we serve. Based in Philadelphia, PA, our company has
established a strategic collaboration and licensing agreement with
the renowned University of Pennsylvania’s Gene Therapy Program to
conduct our discovery and IND-enabling preclinical work. This
provides our team with enhanced access to a broad portfolio of gene
therapy candidates and future gene therapy innovations that we then
pair with our deep clinical, regulatory, manufacturing and
commercial expertise to rapidly advance our robust pipeline of
optimized gene therapies into clinical testing. As we work with
speed and tenacity, we are always mindful of patients who may be
able to benefit from our therapies. More information is available
at www.passagebio.com.
For further information, please contact:
Investors:Stuart HendersonPassage
Bioshenderson@passagebio.com
Media:Gwen FisherPassage
Bio215.407.1548gfisher@passagebio.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Sep 2023 to Sep 2024